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A B S T R A C T
The Neuronal Ceroid Lipofuscinoses (NCLs, Batten disease) are a group of inherited neurodegenerative disorders
with variable age of onset, characterized by the lysosomal accumulation of autoﬂuorescent ceroid lipopigments.
The endoplasmic reticulum (ER) is a critical organelle for normal cell function. Alteration of ER homeostasis
leads to accumulation of misfolded protein in the ER and to activation of the unfolded protein response. ER stress
and the UPR have recently been linked to the NCLs. In this review, we will discuss the evidence for UPR
activation in the NCLs, and address its connection to disease pathogenesis. Further understanding of ER-stress
response involvement in the NCLs may encourage development of novel therapeutical agents targeting these
pathogenic pathways.
1. Introduction
The neuronal ceroid lipofuscinoses (NCLs), also known as Batten
disease, represent a group of lysosomal storage disorders (LSD) with a
worldwide distribution, aﬀecting both children and adults. Thirteen
genetically distinct genes have been identiﬁed that, when mutated,
result in abnormal lysosomal function and an excessive accumulation of
ceroid lipofuscin in neurons and other cell types. The NCL family of
proteins is comprised of four lysosomal enzymes (PPT1/CLN1, TPP1/
CLN2, CTSD/CLN10, CTSF/CLN13), a soluble lysosomal protein
(CLN5), secreted proteins (GRN/CLN11), and several proteins that
display diﬀerent subcellular localisations (CLN3, DNAJC5/CLN4,
CLN6, MFSD8/CLN7, CLN8, ATP13A2/CLN12, KCTD7/CLN14).
Unfortunately, the precise function and localisation of many of the
NCL proteins are still unclear, which has made targeted therapy
development challenging. In this review we present and discuss the
pathogenic role of ER stress in the listed NCL subtypes.
1.1. Neuronal ceroid lipofuscinoses
The NCLs are the most common autosomal recessive neurodegen-
erative storage disorders, and have no eﬀective treatment. The hall-
mark characteristic is the presence of autoﬂuorescent storage material
in lysosomes resembling ceroid and lipofuscin lipopigments that also
accumulate in disease or during the normal ageing process. This storage
material is observed in many tissues and cell types. However, the
pathological eﬀect of the disease is most prominent in the central
nervous system (CNS) and the eyes. There are several types of NCLs,
each of which is caused by mutation in a distinct gene and diﬀer for age
of onset, disease progression and severity, and the morphological
appearance of the storage material [1]. Historically, classiﬁcation of
the NCLs was clinically led according to the age at onset of symptoms:
infantile, late infantile (LINCL), juvenile (JNCL) and adult (ANCL)
NCLs. However, the NCLs are more genetically heterogeneous than
initially thought. Mutations in the same gene can lead to very diﬀerent
disease courses [2]. An internationally developed new NCL nomencla-
ture now clearly identiﬁes each NCL disease both genetically and
clinically [1,3] with diagnosis now highlighting the defective gene as
well as the age at disease onset. To date, more than a dozen diﬀerent
genes have been found to cause NCL [2,4]. Common pathological
characteristics of NCL include progressive visual deterioration leading
to blindness, epilepsy, intellectual and motor decline, with aﬀected
individuals dying prematurely [1]. The ultrastructural appearance of
the storage material is characteristic for diﬀerent types of NCL and has
long been used as a diagnostic tool [1]. Intracellular localisation and
function of the identiﬁed NCL proteins vary: ﬁve NCL types are caused
by defects in soluble lysosomal enzymes or proteins (CLN1; CLN2;
CLN5; CLN10; CLN13), other forms by defects in transmembrane
proteins with various localisations (CLN3; CLN6; CLN7; CLN8;
CLN12; CLN14) [2,4]. In addition, the recently identiﬁed CLN4
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(DNAJC5) and CLN11 (GRN) genes encode, respectively, a cytosolic and
extracellular proteins [2,4] (Table 1). How all these genetic defects lead
to similar clinical symptoms and neurodegeneration is still not clear.
1.2. ER-Golgi transport
Proteins destined for secretion, membranes or organelles begin their
maturation in the ER where they fold, oligomerise, and are frequently
subjected to covalent modiﬁcations in the process of becoming biolo-
gically active. The secretory pathway comprises the endoplasmic
reticulum (ER), ER exit sites (ERES), the ER-to-Golgi intermediate
compartment (ERGIC), the Golgi complex and post-Golgi carriers en
route to their ﬁnal destination. To exit the ER, newly synthesised
proteins must pass a tightly controlled quality check [5]. Proteins that
fail to do so are rerouted to the cytosol for degradation. It is important
to understand the molecular mechanisms that coordinate protein
synthesis, folding, transport and degradation because unbalances in
these processes are the basis of many human diseases. The mechanisms
that direct ER-Golgi cargo ﬂow involve specialised multi-protein
machineries. The three main vesicular frameworks are COPII, COPI
and clathrin-based.
COPII-coated vesicles transport cargo proteins from the ER to the
Golgi; COPI-coated vesicles transport cargo in the retrograde direction
(from the cis-Golgi back to the ER) and between Golgi cisternae.
Clathrin-coated vesicles form at the plasma membrane and the trans-
Golgi network (TGN) and subsequently fuse with endosomes or
lysosomes. By coupling cargo selection to vesicle formation, cells can
achieve eﬃcient protein sorting as an in-built outcome of the transport
pathway itself. In addition, some cargoes exit the ER without concen-
tration into vesicles or interaction with the vesicle coat [6].
Understanding how protein-folding inﬂuences ER–Golgi traﬃc is
crucial, since premature exit from the ER results in a lack of folding and
of access to the degradation machinery. Cargo adaptors and cargo
receptors in both the ER and Golgi could play direct roles in determin-
ing the ﬁdelity of transport. ER receptors discriminate between fully
folded proteins and those that need further chaperone action; Golgi
receptors bind misfolded cargo for retrieval back to the ER. However,
whilst this general role may suﬃce for some misfolded proteins it is
unlikely to apply to all proteins. Many incompletely folded proteins are
actually transport-competent beyond the ER [7]. This may be because
some ER export signals are simple peptides extending from the
cytoplasmic side of the membrane and it is unlikely that their
recognition is strongly inﬂuenced by protein folding on the luminal
side of the membrane. Therefore, some misfolded proteins may be
recognised as normal by the export machinery. It is more accurate to
describe the ER exiting process as a dynamic event under the control of
multiple competing interactions, such as ER export and retention
signals and ER associated degradation (ERAD). Furthermore, under
severe ER stress condition, sorting signals can be used as an ER
detoxiﬁcation pathway [8]. Understanding the interplay between these
pathways lies at the heart of numerous misfolding diseases that stem
from defects in quality control of protein sorting at the ER–Golgi
interface.
1.3. Endoplasmic Reticulum (ER) stress response
The ER is a complex, dynamic organelle and is the ﬁrst compart-
ment in the secretory pathway responsible for the synthesis, modiﬁca-
tion and export of newly synthesised proteins. The ER is also involved
in Ca2+ storage, lipid and carbohydrate metabolism. Cellular stress,
induced by internal or external cues, activates several orchestrated
processes aimed at either restoring cellular homeostasis (adaptive UPR)
or committing to cell death (maladaptive UPR). Those processes named
‘ER stress response’ comprise various aspects such as unfolded protein
response activation, autophagy, and mitochondrial response. When one
of the elements of the ER stress response is impaired, as often occurs
under pathological conditions, overall cellular homeostasis may be
perturbed [9]. The quality control mechanism of the ER is therefore
essential to ensure that only properly folded proteins exit the ER.
1.3.1. The unfolded protein response (UPR)
The overall protein folding status is relayed to the cytosol, nucleus
and other organelles such as lysosomes and mitochondria. During times
of ER stress, protein load and translation are decreased and the folding
capacity of the ER increased in an attempt to restore the ER equili-
brium. To reduce the protein load, transcription of genes encoding
secretory proteins is downregulated, misfolded proteins are cleared
through ERAD, and a general reduction of protein translation is
imposed at the ER. More chaperones are synthesised and the volume
of the ER is increased in order to dilute the unfolded protein load and to
host more chaperone machineries in an attempt to increase the protein
folding capacity. If the aforementioned mechanisms fail to rescue and
restore cell homeostasis then apoptosis could be triggered through the
intrinsic pathway in an attempt to prevent further damage at the level
of tissue or organism [9].
The protein folding machinery of the ER consists of three classes of
proteins, foldases, molecular chaperones and lectins. Foldases directly
promote protein folding and molecular chaperones prevent protein
Table 1
Summary of the identiﬁed genes causing human NCL disease. In bold are the genes linked to ER stress discussed in this review.
Gene Protein Protein solubility Protein localisation Linked to ER stress Refs
CLN1 PPT1
Palmitoyl protein thioesterase1
Soluble Lysosomal matrix Yes [27,60,62,63,66]
CLN2 TPP1
Tripeptidyl peptidase1
Soluble Lysosomal matrix Unknown
CLN3 CLN3 Transmembrane Golgi/ Lysosome Yes [75–78,80,81]
CLN4 DNAJC5 Soluble Cytosolic, associated with vesicular membrane, Unknown
CLN5 CLN5 Soluble Lysosomal matrix Unknown
CLN6 CLN6 Transmembrane ER-membrane Yes [86,88,89]
CLN7 MFSD8
Major facilitator superfamily domain-containing protein-8
Transmembrane Lysosomal membrane Unknown
CLN8 CLN8 Transmembrane ER-membrane Yes [86,93,98–101]
CLN10 CTSD
Cathepsin D
Soluble Lysosomal matrix Unknown
CLN11 GRNProgranulin and granulins Soluble Extracellular Unknown
CLN12 ATP13A2 Transmembrane Lysosomal membrane Unknown
CLN13 CTSF
Cathepsin F
Soluble Lysosomal matrix Unknown
CLN14 KCTD7 Transmembrane Partially associated with plasma membrane Unknown
⁎CLN9 gene has been postulated but not yet identiﬁed [104].
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aggregation by shielding unfolded regions. The ER-resident chaperones
comprise the HSP70 family, GRP78, LHS1/GRP170, their co-chaper-
ones, which belong to the DnaJ and GrpE families, and an HSP90
paralogue, HSP90B1, which recognises partially folded proteins [10].
Lectins function as chaperone and sorting receptors in the secretory
pathway. Calnexin and calreticulin are ER-speciﬁc lectins that recog-
nise terminal glucose residues on high-mannose N-linked glycans [11].
Prolonged interaction of a native protein with the chaperone machinery
is a key step in inducing the unfolded protein response.
Three ER membrane sensors regulate the UPR: inositol-requiring
enzyme 1 (IRE1), activating transcription factor 6 (ATF6) and double-
stranded RNA-activated protein kinase-like ER kinase (PERK), all of
which can be activated by perturbed ER homeostasis. Each activates
specialised transcriptional programmes mediated by distinct transdu-
cers [9]. Two forms of IRE1 are present in mammals: IRE1α is expressed
ubiquitously while IRE1β is expressed only in the intestinal and lung
epithelium [12]. The transcription factor downstream of IRE1α, XBP1,
activates target genes involved in protein folding and the major
chaperones BiP/GRP78 and GRP94 [13]. IRE1 is also linked to
apoptosis via activation of the Jun/JNK pathway [14]. ATF6 is an ER
transmembrane protein that is internalised and transported to the Golgi
complex upon ER stress. Once in the Golgi ATF6 is cleaved by Site-1
protease (S1P) and Site-2 protease (S2P), liberating the N-terminal
cytosolic fragment, ATF6(N), which translocates to the nucleus to
activate UPR target genes [15]. Interestingly, there is a relationship
between S1P and lysosomal function. Absence of S1P results in lack of
cleavage and activation of the α/β-subunit precursor of the hexameric
N-acetylglucosamine-1-phosphotransferase complex leading to abnor-
mal sorting of newly synthesised lysosomal proteins and accumulation
of storage material in the lysosomes, a similar phenotype to that
observed in mucolipidosis type II (MLII) [16]. ATF6(N) targets genes
involved in protein folding such as BiP/GRP78, protein disulphide
isomerase (PDI) and glucose-regulated protein 94 (GRP94), and protein
degradation such as components of the ERAD [15]. Increased expres-
sion of molecular chaperones and of degradation enzymes helps to
relieve the ER from the stress (Fig. 1).
PERK, an ER transmembrane kinase, functions as an ER-stress
sensor, inﬂuencing redox homeostasis and the ER-mitochondria inter-
face [17,18]. Upon ER stress, PERK oligomerises, auto-phosphorylates,
and phosphorylates the α subunit of the eukaryotic initiation factor 2
(eIF2α) (Fig. 1). eIF2α phosphorylation leads to a temporary attenua-
tion of overall protein translation and to an upregulation of the
transcription factor ATF4. This translation inhibition decreases the
load of proteins entering the ER in an attempt to alleviate the ER stress
and therefore playing an adapting role in direct response to ER stress. In
addition, the PERK pathway plays a master and dual role in apoptosis.
Increased expression of the transcription factor ATF4 upregulates C/
EBP homologous protein (CHOP) and DNA damage-inducible 34 (G-
ADD34) (Fig.1) [19]. CHOP promotes ER stress-induced apoptosis and
GADD34 is involved in a negative feedback loop that counteracts PERK
by dephosphorylation of eIF2α, allowing protein synthesis to resume
and triggering apoptosis (Fig. 1) [20]. In addition, activation of PERK
can lead to downregulation of anti-apoptotic protein XIAP, through
eIF2α and ATF4, causing an increase in apoptosis [21] (Fig. 1).
However, PERK also functions in preventing ER-stress induced apopto-
sis. PERK activates the cytoplasmic inhibitors of apoptosis proteins
(cIAPs), regulating the cross talk that inﬂuences UPR determination of
cell fate under ER stress (Fig. 1) [22]. In addition, PERK is required to
regulate inter-organelle cross talk in reactive oxidative species-induced
cell death (paragraph 1.3.2) and is a molecular mediator of the ER-
mitochondria contact sites (paragraph 1.3.4) [18]. It is still unclear if in
this context PERK is acting as a UPR mediator or independently from
the ER stress response [23].
1.3.2. ER stress and apoptosis
Apoptosis is a highly sophisticated and regulated programme that
requires activation of diﬀerent molecular events. Studies indicate that
there are two main apoptotic pathways: extrinsic (death receptor
pathway) and intrinsic (mitochondrial pathway). The extrinsic pathway
is triggered by transmembrane receptors belonging to the tumor
necrosis factor (TNF) superfamily. These receptors contain a cytoplas-
mic “death domain” that transmits a signal from the cell surface into the
cell, activating a signal cascade that culminates in activation of caspase
8. Activated caspase 8 cleaves downstream substrates including other
caspases, thereby activating the execution phase of the apoptotic
process [24]. The intrinsic pathway can be triggered by diﬀerent
signals resulting in alteration of the mitochondria membrane potential
and release of pro-apoptotic factors. Apoptotic and survival pathways
are tightly controlled and regulated. To counterbalance the apoptotic
pathways, cells express a variety of anti-apoptotic factors that counter-
act cell degeneration caused by both environmental and genetic insults
[25]. The ﬁne tuning between cell survival and death is regulated by
members of the Bcl-2 family that consist of both anti-apoptotic proteins
such as Bcl-2 and Bcl-xL and pro-apoptotic factors such as Bax, Bak, Bik
and Bim [24]. The anti-apoptotic factor Bcl-2 controls the integrity of
the mitochondrial membrane under normal conditions [24]. The pro-
apoptotic protein Bik largely localises to the ER, whereas Bim translo-
cates to the ER membrane and is important for ER stress-mediated cell
death [26].
In addition, accumulation of a protein called growth-associated
protein 43 (GAP43) in the ER is also able to trigger ER-dependent
apoptosis [27]. GAP43 is a highly palmitoylated protein mainly
expressed in neurons, and an increase in its mRNA has been detected
in patients with amyotrophic lateral sclerosis [28]. Abnormal accumu-
lation of GAP43 within the ER causes stress and UPR activation [27]
and activation of ER-resident caspase 4 [27] leading to apoptosis
through activation of caspase 3 and subsequent cleavage of the
apoptotic eﬀector PARP. Alternatively, the apoptotic pathway can be
activated through elevated production of reactive oxygen species
(ROS), through the role of PERK as ER-mitochondria mediator
[18,27]. ROS production causes release of Ca2+ ions, which destabilise
mitochondrial membranes and activating caspase 9 with subsequent
activation of caspase 3 and cleavage of PARP leading to cell death [27].
In addition, IRE1 pathway activation can lead to Jun/JNK mediated
apoptosis [14]. Upon prolonged stress, the cytoplasmic domain of IRE1
can interact with TRAF2, reﬂecting in a phosphorylation of JNK and
activation of the apoptotic pathway. Conversely, JNK-induced apopto-
sis can amplify the IRE1 signal, via pro-apoptotic factors such as Bax
and Bak [29].
Apoptosis under ER stress is therefore the result of ﬁne-tuning
between diﬀerent branches of the UPR pathway. Whether or not ER
stress culminates in cell death is determined by multiple diﬀerent
factors, such as the intensity and duration of the stress. Evidence for a
role of ER stress-mediated apoptosis in diﬀerent neurodegenerative
diseases make this process an attractive target for therapy. Thus, a
better understanding of the mechanisms that orchestrate the ER stress
mediated apoptosis may help to shape future therapeutic strategies.
1.3.3. ER stress and autophagy
Accumulating data indicate that ER stress is also a potent trigger of
autophagy [30]. Autophagy is a lysosomal pathway involved in the
turnover of cellular macromolecules and organelles. The ﬁrst step of
autophagy is the envelopment of cytosol and/or organelles by the
isolating membrane, which wraps around the cargo forming an
autophagosome, a vesicle surrounded by a double-membrane. The
autophagosome then undergoes progressive maturation following fu-
sion with endolysosomal vesicles to create an autolysosome, where the
cargo is degraded. Autophagy is controlled by a set of evolutionarily
conserved autophagy-related proteins (Atg proteins) [31]. The initial
nucleation and assembly of the primary autophagosomal membrane
requires a kinase complex that consists of class III phosphatidylinositol
3-kinase (PI3K), p150 myristoylated protein kinase and beclin 1 (also
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known as Atg6). Further elongation of the isolating membrane is
mediated by two ubiquitin-like conjugation systems one of which
results in conversion of microtubule-associated protein 1 light chain 3
(LC3; also known as Atg8) from free form (LC3-I) to a lipid-conjugated
membrane-bound form (LC3-II). The accumulation of LC3-II and its
localization to vesicular structures are commonly used as markers of
autophagy [31]. Autophagy is also involved in removing damaged or
excess organelles. For example, mitochondria that have lost their
membrane potential and peroxisomes changing in response to environ-
mental cues can be selectively removed by autophagy [31].
Whereas the induction of autophagy by ER stress is conserved from
yeast to mammals, the signalling pathways responsible for autophagy
induction and its cellular consequences appear to vary according to the
cell type and the stimulus. Recently, it has been shown that the
transcription factors TFE3 and TFEB [32] contribute to UPR and
autophagy. It has been suggested that TFEB and TFE3 may play a dual
role in determining cellular fate. During early stages of ER stress or
cellular starvation, TFEB and TFE3 may promote cell survival by
enhancing expression of genes such as ATF4, promoting expression of
genes required for autophagy, lysosomal biogenesis, and ER home-
ostasis. Under prolonged stress, instead, activation of TFEB and TFE3
leads to ATF4 dependent expression of pro-apoptotic factors [33].
A better understanding of the signalling pathways controlling
autophagy and the cellular fate in response to ER stress will hopefully
open new possibilities for the treatment of the numerous diseases
related to ER stress.
1.3.4. ER stress and mitochondria
Many regulatory members of UPR link with mitochondrial regula-
tion and function [34]. The ER and mitochondria are physically and
functionally connected through mitochondria-associated ER mem-
branes (MAMs). The MAMs are crucial for the regulation of Ca2+
homeostasis in response to a speciﬁc signalling pathway. PERK is
enriched at the ER side of the MAMs where it plays an important role in
integrity [18] and is a regulator of mitochondrial processes such as
ﬁssion and fusion [35]. Despite the function of PERK as ER-mitochon-
dria regulator appearing independent of its role in the UPR, an UPR-
dependent role cannot be excluded [23]. In addition, ATF4, another
member of the UPR response, controls expression of the ubiquitin
kinase Parkin, a key player of mitochondrial function and dynamics
[36]. Parkin has also been increasingly reported in MAM, where it
maintains ER-mitochondrial Ca2+ transfer [37]. In addition, Parkin is
also able to ultimately regulate XBP1 level, modulating therefore
various UPR dependent responses [38].
Moreover, in skeletal muscle ATF6 is an important partner of PCG1
(peroxisome proliferator-activator receptor gamma coactivator 1 al-
pha), which is associated with mitochondrial biogenesis [39].
The link between ER and mitochondrial stress is still under debate
even though defects in this axis have been linked to various neurode-
generative disease [40]. Further studies on this topic will further
understanding of the pathophysiology and the identiﬁcation of poten-
tial therapeutic treatment.
1.4. ER stress and UPR in neurodegenerative disorders
A common feature of many neurodegenerative disorders is the
accumulation and deposit of misfolded and unfolded proteins, which
trigger ER stress aﬀecting neuronal homeostasis and lead to cell death
[41]. The ER stress response underlies numerous adult and paediatric
neurodegenerative diseases such as Parkinson's disease (PD) [42],
Alzheimer's disease (AD) [43], amyotrophic lateral sclerosis [44],
polyglutamine diseases [45], as well as paediatric disorders such as
lysosomal storage diseases (LSD) and hereditary spastic paraplegia
(HSP) [46].
In Parkinson's disease, ER stress together with abnormal protein
degradation plays an important role in the pathophysiology of PD,
Fig. 1. Schematic view of UPR response in mammals. Both survival and pro-apoptotic pathways are depicted in the ﬁgure. Upon disruption of ER homeostasis, three ER stress sensor
proteins (PERK, IRE1and ATF6) and their speciﬁc signalling cascades are activated leading to expression of target genes encoding ER chaperones, foldases, redox enzymes and proteins
involved in ER associated degradation (ERAD) and/or autophagy. When these adaptive responses are not suﬃcient to resolve the ER stress, the maladaptive pathway of UPR is activated,
leading to apoptosis.
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contributing to the selective death of dopaminergic neurons [42].
Similarly, in Alzheimer's disease ER stress and altered Ca2+ home-
ostasis [47] have been demonstrated to be part of the etio-pathogenesis
of the disease. However, ER stress activation is not a distinctive feature
of PD and AD. Indeed, in amyotrophic lateral sclerosis elevated levels of
ROS and Ca2+ caused by accumulation of toxic products are able to
trigger ER stress eventually leading to motor neuron loss [44]. In
addition, expanded polyglutamine (PolyQ) repeats in diﬀerent proteins
can cause inherited neurodegenerative disease such as: Huntington's
disease, spinobulbar muscular atrophy, dentatorubral-pallidoluysian
atrophy and at least six spinocerebellar ataxias. These diseases are
characterized by accumulation of intracellular protein aggregates, ER
stress and selective neuronal death [45].
ER stress has been shown to play a role also in the pathophysiology
of paediatric diseases such as hereditary spastic paraplegia (HSP), an
infantile inherited autosomal dominant neurological disorder charac-
terized by spastic weakness of the lower extremities [46], and LSD.
There are at least 50 diﬀerent disorders classiﬁed as paediatric LSD,
including: GM1-gangliosidosis, Pelizaeus-Merzbacher disease (PMD) and
the NCLs. Evidence suggests that ER stress and the UPR response
accompany GM1-gangliosidosis [48] and Pelizaeus-Merzbacher disease
(PMD) [49]. These diseases are characterized respectively by accumu-
lation of GM1-ganglioside [48] and hypomyelination of the central
nervous system [49].
In addition, various reports suggested a link between ER stress and
four forms of NCL disease (CLN1, CLN3, CLN6 and CLN8) (Table 1). For
the remaining genes involved in the NCLs a link with ER stress is less
clear. No link with ER stress has so far been demonstrated for ﬁve NCL
genes (CLN2, CLN5, CLN7, CLN12 and CLN14), although investigations
have not been exhaustive. However, for four other NCL subtypes (CLN4,
CLN10, CLN11 and CLN13) a correlation with the ER stress could be
hypothesised based on existing observations, although no formal
evidence is available yet. Mutations in the CLN4 gene cause the adult
onset form of NCL known as Kufs disease. CLN4 or DNAJC5 encodes
cysteine-string protein α (CSPα). CSPα is a chaperone that ensures
protein folding [50]. Mutations in CSPα could cause accumulation of
unfolded presynaptic proteins that then trigger UPR. CLN11/GRN
(progranulin) has been suggested to play a role in lysosomes [51] and
autophagy under nutrient-starvation, decreasing mTORC1 and TFEB
[52,53], therefore suggesting a potential link to ER stress. Mutations in
CLN13 (CTSF) [54] and CLN10 (CTSD) have been tightly related to
protein degradation, apoptosis and autophagy [55], also hinting at a
potential role of ER stress in the pathogenesis.
As mentioned earlier, a strong correlation between ER stress and the
disease gene has been described in four NCLs subtypes: CLN1, CLN3,
CLN6 and CLN8 diseases. We now review the pathogenetic role of ER
stress in these listed NCL subtypes (Fig. 2).
2. NCL proteins and ER stress
2.1. CLN1/PPT1
Most cases of infantile NCL are caused by inactivating mutations in
palmitoyl-protein thioestarase-1 (PPT1), encoded by PPT1/CLN1 [56].
PPT1 is a lysosomal protein that catalyses the cleavage of thioester
linkages in reversible S-acylated (palmitoylated) proteins, facilitating
the degradation and/or recycling of these lipid-modiﬁed proteins [57].
Children aﬀected by classic CLN1 disease manifest symptoms at
6–12 months, with brain atrophy causing cognitive and motor impair-
ment by 2 years of age and death by 10–12 years of age [58]. However,
some mutations cause a more prolonged disease of later onset such as
juvenile and adult CLN1 disease [59].
It has been reported that some PPT1 variants containing disease-
causing mutations are not correctly transported to the lysosomes, but
are retained in the ER due to improper folding [60] where they are
presumably degraded. For others, transport to the lysosome may still
occur but the enzyme activity is abolished due to loss of the catalytic
site. Moreover, elevated neuronal levels of apoptosis have been
reported in both brain biopsy [61] and in cultured cells from CLN1
patients [62]. Apoptosis, in CLN1 disease, has been proposed to be
caused by ER stress-mediated caspase activation [27,63] as well as
production of ROS that cause Ca2+ dyshomeostasis with activation of
caspase 9 and 3 [27]. Tissues from mice deﬁcient in PPT1 have
abnormal ER morphology, activation of UPR and undergo apoptosis
via activation of caspase 3 [64]. These observations suggest that
apoptosis arising from ER stress is a major cause of cell death in
CLN1 disease. In addition, treatment with a chemical chaperone such as
trimethylamine N-oxide dihydride (TMAO) or tauroursodeoxycholic
acid (TUDCA) [65] signiﬁcantly decreases apoptosis in cells from CLN1
patients suggesting that UPR may be a primary target for CLN1 disease
treatment [66]. Exactly how decreased or absent PPT1 activity in the
lysosome causes ER stress remains to be understood. It may be due to
lysosomal-ER cross talk that directly connects the consequences of
aberrant lysosomal depalmitoylation with the ER, or a consequence of
the more general disruption of lysosomal homeostasis on the cell that
disturbs normal ER function. Regardless, mutations in PPT1 lead to
activation of ER stress and UPR and may provide targets for therapeutic
development.
2.2. CLN3
The majority of juvenile cases of NCL, with an age of onset ranging
between 5 and 7 years of age, are caused by mutations in the CLN3
gene. More than 40 disease-causing mutations have been identiﬁed in
CLN3 (http://www.ucl.ac.uk/ncl) [4] however the majority of CLN3
disease patients carry a 1 kb deletion [1] with around 74% homozygous
for this mutation and about 22% compound heterozygous for this and
another rarer mutation [67]. The 1 kb deletion in CLN3 results in
multiple transcripts that include a frame-shift and premature termina-
tion or loss of several internal exons and an in-frame C terminus and
retained protein function [68]. There are also studies showing that
mutant transcripts of CLN3 are targeted for nonsense decay, and
absence of mutated proteins [69,70]. CLN3 encodes a 438 amino acid
transmembrane protein and despite being identiﬁed more than two
decades ago, the function of this highly conserved protein remain
elusive. Levels of endogenous CLN3 protein are extremely low. A
signiﬁcant localisation of the CLN3 orthologue of ﬁssion and budding
yeasts, Btn1p, has been shown at the Golgi complex [71] and also
reported for GFP-tagged CLN3 in mammalian cells [72]. Moreover,
untagged CLN3 has been shown to localise at late-endosomes and
lysosomes [73]. However, the functional localisation of CLN3 is still
matter of debate. Although, the function of CLN3 remains unknown, a
variety of studies have shown that CLN3 inﬂuences many cellular
processes including protein traﬃcking [74], lysosomal homeostasis
[75] mitochondrial functions [76] Ca2+ homeostasis and autophagy
[77]. CLN3 disease neuropathology is associated with excessive neuro-
nal and photoreceptor cell apoptosis [78]. In addition, previous study
has suggested that CLN3 is an anti-apoptotic gene in neuronal precursor
cells and in at least some cancers [79]. When using Drosophila as a CLN3
disease model, ER and mitochondrial functions were found to be
impaired by oxidative stress [80]. Furthermore, the apoptosis leading
to the neurodegeneration central to CLN3 disease may be caused by
improper management of the response to ER stress [81]. Indeed, it has
been shown that overexpression of wild-type CLN3 enhanced expres-
sion of the ER chaperone protein, glucose-regulated protein 78
(GRP78), and reduced expression of the proapoptotic protein CCAA-
T/-enhancer-binding protein homologous protein [81]. In contrast,
overexpression of mutant CLN3 or siRNA knockdown of CLN3 produced
the opposite eﬀect. Together, the evidence suggests that lack of CLN3
function in cells leads to a failure of management of the response to ER
stress [81].
Recently, it has been shown that treatment of lymphoblast cells
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from patients with ﬁbrates, drugs able to induce peroxisome prolif-
erator-activated receptor-α (PPAR-α) activation, abrogates the depolar-
ization of mitochondrial membrane potential, normalises defective
autophagy and increases overall cell viability [82].
Together, the evidences so far therefore strongly suggest that ER
stress activation may play a pivotal role in the pathogenesis of CLN3
disease, and certainly this requires further study.
2.3. CLN6
There is little current understanding of how mutations in CLN6
cause CLN6 disease [83], which is typically of late infantile onset but
may also arise in adulthood [84]. CLN6 is a 311 amino acid transmem-
brane ER protein (27 kDa) of unknown function and with no conserved
homologous proteins [83,85]. The function of CLN6 has been associated
with autophagy, regulation of pH and endocytosis [86]. CLN6 is
retained in the ER with no observed localisation to the lysosome and
no eﬀect on the synthesis, sorting nor proteolytic processing of the
lysosomal enzyme cathepsin D in ﬁbroblasts from patients with CLN6
disease, sheep (OCL6) or mouse (nclf) models [87]. However, the
lysosomal enzyme arylsulfatase A responsible for the lysosomal hydro-
lysis of sulfatides, is reduced in mutant CLN6 cell lines [87].
Accumulation of biometals such as zinc, copper, manganese and
cobalt has been described in Merino and South Hampshire sheep
models of CLN6 disease [88,89], as well as in the spinal cord, brain
cortex, heart and liver of a Cln6nclf mouse disease model which carries a
1 bp insertion in the orthologous gene [90]. Aberrant biometal meta-
bolism is a common feature observed in other neurodegenerative
disorders such as Alzheimer's and Parkinson's disease [91]. Further
research eﬀorts are needed to clarify the precise function of CLN6.
Nevertheless, the selective neurodegeneration arising from CLN6
deﬁciency could be linked to this accumulation of biometals, especially
to zinc. Zinc is a key modulator of intracellular and intercellular
neuronal signalling, and zinc dyshomeostasis can cause neuronal cell
death. Substantial progressive loss of the ER/Golgi-resident Zn trans-
porter, Zip7, which colocalises with CLN6, may contribute to the
subcellular deregulation of biometal homeostasis in NCL disease.
Importantly, the metal-complex ZnII(atsm) that is protective in amyo-
trophic lateral sclerosis-induced Zip7 upregulation, promotes Zn redis-
tribution and restores Zn-dependent functions in primary mouse Cln6
deﬁcient neurons and astrocytes [89]. Both ER and oxidative stress
have been observed in CLN6 disease [88]. It is possible that biometal
dyshomeostasis impairs processing of protein folding, causing activa-
tion of ER stress with subsequent apoptosis. In addition, it has been
reported that TRAM1, a protein involved in translocation of nascent
polypeptides during ER stress, is also upregulated during UPR causing
the rapid degradation of CLN6 mutants [92]. Altogether, this evidence
implicates ER quality control in the stability of CLN6 variants and a
likely contribution to the pathogenesis of CLN6 disease.
2.4. CLN8
CLN8 is mutated in two distinct clinical NCL phenotypes: late
infantile and a mutation-speciﬁc juvenile-onset variant, progressive
epilepsy with mental retardation (EPMR) also known as Northern
Epilepsy [93]. Like CLN6, CLN8 is an ER-resident transmembrane
protein of predicted 286 amino acid residues containing 5 hydrophobic
regions including a TLC (TRAM-LAG1-CLN8) domain. It is recycled
between the ER and ER- Golgi intermediate compartment (ERGIC)
using an ER-retrieval signal (KKRP) in its cytoplasmic C-terminus in
non-neuronal cells [94–96]. Mutations in CLN8 do not appear to aﬀect
its localization at the ER but it has been observed outside the ER in a
specialised sub-compartment of the polarised epithelial Caco-2 cells
[97], in the Golgi, endosomes and lipid rafts of mouse ﬁbroblasts, in a
light membrane fraction diﬀerent from ER after fractionation of mouse
brain, as well as in the proximity of the plasma membrane in
hippocampal neurons. Although not delineated, the function of CLN8
has been linked to lipid homeostasis [86]. This may provide a link
between CLN8 mutants and ER stress, as the UPR can be regulated by
lipids and also plays a role in regulating lipid metabolism [98]. ER
stress may therefore play a crucial role in the pathogenesis of the
disease. BiP/GRP78, CHOP, and ATF6 are upregulated with activation
of caspase 12 in the CNS and retina of the naturally occurring Cln8mnd
mouse model, which exhibits a disease phenotype similar to that of late-
Fig. 2. Mutations in three transmembrane proteins (CLN3, CLN6 and CLN8) and one lysosomal enzyme (CLN1) cause distinct types of NCL that include activation of ER stress, eventually
leading to apoptosis.
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infantile CLN8 disease patients [93,99]. In addition in mnd mice
defective lipids and protein transport and ER/mitochondria Ca2+
exchange are linked to alteration in MAMs [100].
Recently, molecular partners of CLN8 have been described to be
involved in autophagy, apoptosis, as well as vesicular traﬃcking and
lipid transport [101]. All this evidence together therefore strongly
suggests that apoptosis induced by ER stress activation may play a
pivotal role in the pathogenesis of CLN8 disease, and certainly deserves
further study.
3. Conclusions
Experimental evidences suggest that several organelles are capable
of sensing and relaying pro-apoptotic signals, culminating in the
proteolytic activation of caspases and cell death. Each organelle is
likely to be uniquely poised and equipped to sense speciﬁc stimuli
related to their function and structure. For example, the ER is the major
site for folding, modiﬁcation and assembly of newly synthesised
proteins and has evolved a stress response pathway to cope with the
accumulation of unfolded or misfolded proteins. Activation of ER stress
has been shown to induce the expression of chaperones, attenuate
translation and degrade misfolded proteins in attempt to alleviate the
stress. Prolonged ER stress results in irreparable damage leading to
apoptosis. This is the case observed in some of the NCL types described
in this review (Fig. 2). Indeed, a mismanagement of the ER stress
response leading to apoptosis is detectable in several types of NCLs
(CLN1, CLN3, CLN6 and CLN8), with common pathways aﬀected such
as protein folding and build-up, ROS production, and caspase activa-
tion.
In CLN1 disease, both ROS and Ca2+ dyshomeostasis contribute to
ER stress activation. In CLN3 disease, ER-stress mediated apoptosis
might play an important role. A global screen to identify genetic
interactions with the ﬁssion yeast orthologue btn1 highlighted a
conserved key signalling hub in which multiple components function-
ally relate to this conserved disease gene [102]. This signalling hub
includes two major mitogen-activated protein kinase (MAPK) cascades,
and centres on the Tor kinase complexes TORC1 and TORC2. Yeast cells
modelling CLN3 disease exhibit features consistent with dysfunction in
the TORC pathways. Wild type yeast cells respond to a variety of
stresses via interconnected signalling pathways restoring cell home-
ostasis and integrity. In contrast, cells lacking btn1 are unable to
respond to the applied stresses, although the pathways themselves are
still functional [102]. Thus, for CLN3 disease at least, neuronal cell
death could be triggered by the inability of key signalling pathways to
be activated, such as a dysfunctional mTORC1 pathway causing
apoptosis through suppression of Akt and consequent induction of the
IRE1–JNK pathway [103].
In CLN6 disease in particular, accumulation of biometals could lead
to ER-stress. Biometals such as Mn2+ are important cofactors for
protein post-translational modiﬁcation, with defects in manganese
homeostasis leading to misfolding of proteins and their accumulation
in the ER and ER stress. In CLN8 disease, a mismanagement of the ER
stress response is linked with lipid homeostasis and alteration of MAMs.
To date, the evidences reported are strongly suggestive that the
dramatic neuronal loss observed in NCLs is caused by ER stress-
mediated apoptosis, making this process an attractive target for
therapy. The apoptotic pathway is not one single linear path, but is a
complex and articulated pathway that can be activated via diﬀerent
stimuli and branches of the UPR. Given the various localizations and
functions of the diﬀerent CLN proteins, we cannot exclude that their
mutation challenges the quality control and activates the ER stress/UPR
in slightly diﬀerent ways, but still resulting in a similar apoptotic
phenotype. In addition, some mutant proteins are transport competent
but not functional once reaching their ﬁnal destination. Therefore, a
better understanding of the interplay between the various pathways
leading to the apoptotic pathway and arising from defects in the quality
control process as well as how some proteins may escape quality control
in the ER could greatly contribute to elucidating the pathogenesis of the
various NCL diseases and provide speciﬁc therapeutic approaches. In
addition, it is possible that alteration in one NCL gene inﬂuences the
expression and localization of other NCL proteins, thereby generating a
complex scenario in which modulation of the phenotype of various NCL
diseases is the result of the combined alteration of expression of
diﬀerent NCL proteins.
3.1. Implications for treatment
The UPR pathway represents a possible common target to treat
multiple forms of NCL disease. Therapeutically, it is therefore crucial to
understand the role of the UPR in the pathogenesis of the NCLs. In
addition, the pharmacological modulation of UPR, either by pro-
apoptotic or pro-survival signalling, could provide new treatment
strategies not only for the NCLs but many diseases, including other
neurodegenerative disorders, heart disease and cancer.
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